<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04660058</url>
  </required_header>
  <id_info>
    <org_study_id>KY20202100-F-1</org_study_id>
    <nct_id>NCT04660058</nct_id>
  </id_info>
  <brief_title>Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer</brief_title>
  <official_title>Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer: A Case-control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital of Digestive Diseases</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the associations among bile acid profile, bile acid-microbiota cross-talk and the&#xD;
      development of gastric cancer, so as to better prevent the occurrence and development of&#xD;
      gastric cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a case-control study. Patients, according to the pathological results, will be&#xD;
      consecutively enrolled and divided into gastric cancer group, gastric precancerous lesions&#xD;
      group, and chronic gastritis group. The serum and gastric juice bile acid profiles, gastric&#xD;
      microbial composition of each group patients will be detected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>corelation between the bile acid profile and gastric mucosa diseases</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Investigators evaluate the corelation between the bile acid profile and gastric mucosa diseases according to the results of UPLC-MS/MS and pathological .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>corelation between the bile acid profile and gastric microbiota in different groups</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Investigators explore the cross-talk between bile acid and gastric microbiota according to the results of 16s rRNA sequencing</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bile Reflux</condition>
  <condition>Gastric Cancer</condition>
  <condition>Precancerous Lesion</condition>
  <arm_group>
    <arm_group_label>chronic gastritis</arm_group_label>
    <description>patients with chronic non-atrophic gastritis and chronic atrophic gastritis according to histopathological results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>precancerous lesion</arm_group_label>
    <description>patients with gastric intestinal metaplasia and intraepithelial neoplasia according to histopathological results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gastric cancer</arm_group_label>
    <description>patients with gastric cancer according to histopathological results</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum and gastric juice samples will not be retained; pathological tissue samples will be&#xD;
      retained in Xijing Hospital&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients are from Xijing Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 75 years old, gender is not limited;&#xD;
&#xD;
          2. No history of antibiotic or probiotic use for 8 weeks;&#xD;
&#xD;
          3. No preoperative chemotherapy or radiation therapy prior to the examination;&#xD;
&#xD;
          4. Voluntary intravenous blood collection, gastroscopy, extraction of gastric juice and&#xD;
             pathological biopsy.&#xD;
&#xD;
          5. Voluntary testing for H. pylori&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. had undergone upper gastrointestinal and colon surgery;&#xD;
&#xD;
          2. Previous diagnosis of Malignant Tumors;&#xD;
&#xD;
          3. Presence of a disease or medication that affects bile acid metabolism, such as&#xD;
             endocrine or autoimmune diseases;&#xD;
&#xD;
          4. Recent use of drugs that affect gastrointestinal motility;&#xD;
&#xD;
          5. Presence of contraindications to endoscopy;&#xD;
&#xD;
          6. pregnant and lactating women;&#xD;
&#xD;
          7. Those with mental disorders;&#xD;
&#xD;
          8. Refusal to sign the informed consent form.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Xijing Hosipital of Digestive Disease</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xijing Hospital of Digestive Diseases</investigator_affiliation>
    <investigator_full_name>Yongquan Shi</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>bile acid</keyword>
  <keyword>gastric microbiota</keyword>
  <keyword>Gastric Cancer</keyword>
  <keyword>precancerous lesion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Bile Reflux</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

